Welcome to our dedicated page for NKGEN BIOTECH news (Ticker: NKGN), a resource for investors and traders seeking the latest updates and insights on NKGEN BIOTECH stock.
NKGen Biotech develops clinical-stage natural killer cell therapeutics, with news centered on troculeucel, its patient-specific, ex vivo expanded autologous NK cell immunotherapy candidate also known as SNK01. Company updates commonly address Alzheimer’s disease, frontotemporal dementia and cancer development, including conference presentations, clinical and biomarker analyses, mechanistic data and regulatory naming for the program.
Recurring disclosures also cover NKGen’s OTC quotation and trading status, capital-market communications, scientific advisory activity and its majority-owned Korean affiliate, NKGen Biotech Korea Co., Ltd., which develops NK cell therapies and commercializes bioreagents and immunodiagnostic technologies.
NKGen Biotech (NKGN) will present its lead investigational NK cell therapy, troculeucel, for neurodegenerative diseases at the 4th Great Bay Cell and Gene Therapy Forum on September 22–23, 2026, in Guangzhou, China.
Chairman and CEO Paul Y. Song, M.D., will speak on September 23, 2026, at 9:35–10:00 a.m. CST (September 22, 9:35–10:00 p.m. ET) in Ballroom A, covering troculeucel’s proposed mechanism of action, cerebrospinal fluid biomarker changes, and clinical experience in Alzheimer’s disease, with Parkinson’s disease and frontotemporal dementia as areas for further evaluation.
NKGen Biotech (NKGN) will present on its lead investigational NK cell therapy troculeucel for neurodegenerative diseases at Biologics Manufacturing Korea 2026. The talk, by Chairman and CEO Paul Y. Song, M.D., is scheduled for September 18, 2026, 11:00–11:25 a.m. KST (September 17, 2026, 10:00–10:25 p.m. ET).
The presentation will cover troculeucel’s mechanism of action in reducing cerebrospinal fluid neuroinflammatory and protein biomarkers, clinical experience in Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia, and the regulatory landscape in Asia. Troculeucel is a patient-specific, ex vivo expanded autologous NK cell drug candidate, also known as SNK01, and has been assigned an International Nonproprietary Name by the WHO.
NKGen Biotech (OTC:NKGN) will present at the 2026 BIOCHINA Global Forum in Seoul on July 10, 2026.
Chairman and CEO Paul Y. Song, M.D. will discuss troculeucel, an enhanced autologous NK cell therapy in Phase 2 for Alzheimer’s and other neurodegenerative diseases, plus China regulatory and partnership opportunities.
NKGen Biotech (OTC:NKGN) activated three new U.S. clinical trial sites for its ongoing Phase 2 trial of troculeucel in moderate Alzheimer’s disease. New locations in New Jersey, New York, and Florida broaden geographic reach, improving access for patients and physicians and potentially supporting enrollment across multiple regions.
NKGen Biotech (OTC:NKGN) will present mechanistic and early clinical data for lead candidate troculeucel at the 8th Annual Neuroimmunology Drug Development Summit, April 14-16, 2026.
The presentation on April 16, 2026 at 11:00 AM ET will describe selective targeting of autoreactive T cells, biomarker trends, and reductions in cerebrospinal fluid neuroinflammatory signals.
NKGen Biotech (OTC: NKGN) reported pooled Phase 1 troculeucel data presented at AD/PD 2026 showing dose‑responsive cognitive improvements and biomarker correlations in Alzheimer’s disease. In moderate AD patients (n=6) 100% were stable or improved at three months and 50% improved from moderate to mild on CDR‑SB.
Exploratory plasma GFAP correlated with clinical measures (r up to 0.76, p≤0.009) and higher doses (4–6B cells) showed stronger associations; two patients had maintained benefit through 12 months. No treatment‑related adverse events were reported.
NKGen Biotech (OTC: NKGN) will present integrated Phase 1 clinical and biomarker analyses for troculeucel in Alzheimer’s disease at AD/PD 2026 (March 17–21, 2026) in Copenhagen and virtually. Presentations include an oral symposium talk on March 21 and a poster on March 20–21 examining cognition and plasma GFAP associations. The analyses combine patient-level data from two completed Phase 1 trials to assess dose-response on cognitive measures and GFAP biomarker correlations. These data do not include the company’s ongoing Phase 2 trial results.
NKGen Biotech (OTC: NKGN) appointed Bruce L. Miller, M.D. to its Scientific Advisory Board on January 22, 2026. Dr. Miller is a leading expert in Alzheimer’s disease, frontotemporal dementia (FTD), and neurocognitive disorders and directs the Edward and Pearl Fein Memory and Aging Center at UCSF.
The company said Dr. Miller will advise clinical and scientific priorities as NKGen advances its Phase 2 trial of autologous NK cell therapy troculeucel in moderate Alzheimer’s disease and explore troculeucel use in FTD after early expanded-access signals.
NKGen Biotech (OTC: NKGN) announced board changes at its majority-owned Korean affiliate NKGen Korea following a shareholder-approved name change on November 21, 2025. NKGen Korea disclosed KOSDAQ appointments of Hanhan Xu, Xuan Zhang, and Dr. June H. Lee to three-year terms, and earlier appointed Dr. Angie You on August 14, 2025 to a one-year term. Leadership backgrounds span scientific development, operations, finance, and venture roles across Asia and the U.S.
The company said it supports the appointments as majority shareholder and expects the new directors to aid NKGen Korea as it emerges from rehabilitation and advances NK cell therapeutic development and commercialization in the Asia-Pacific region.
NKGen Biotech (OTC: NKGN) clarified that recent $0.00 price displays on some financial sites reflect quote dissemination limits on the OTC Expert Market, not the company’s underlying value. Quotations were moved to the OTC Expert Market on or about July 17, 2025 after the company failed to remain current in Exchange Act filings. The company confirmed its common stock remains listed and tradable, but public price quotes and volume are restricted to broker‑dealers and institutions. NKGen filed its Form 10‑K on October 8, 2025 and is working to file Form 10‑Qs for the quarters ended Mar 31, Jun 30, and Sep 30, 2025 to regain compliance and restore public market data access.